Circulating tumor cells in newly diagnosed inflammatory breast cancer
Michal Mego(Comenius University Bratislava), James M. Reuben(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Antonio Giordano(University of Siena), Massimo Cristofanilli(Cornell University), Hiroko Masuda(SHOWA Medical University), Mario Giuliano(Regione Campania), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Shaheenah Dawood(Mediclinic City Hospital), Tamer M. Fouad(The University of Texas MD Anderson Cancer Center), Ricardo H. Álvarez(The University of Texas MD Anderson Cancer Center), Eleni Andreopoulou(Cornell University), Limin Hsu(The University of Texas MD Anderson Cancer Center), Wendy A. Woodward(The University of Texas MD Anderson Cancer Center)
Cited by 45
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k